CIRM Funded Clinical Trials

Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)


Michael Matthay
Disease Area: 
COVID-19
Investigator:
CIRM Grant:
CLIN2COVID19-11823 (Pre-Active)
Award Value:
$750,000
Trial Sponsor:
University of California, San Francisco
Trial Stage: 
Phase 2
Trial Status: 
Recruiting
Targeted Enrollment:
120
ClinicalTrials.gov ID:
Details: 

Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that occurs when fluid leaks into the lungs.  As a result, breathing becomes difficult and oxygen cannot get into the body.  ARDS is one of the most serious and lethal consequence of COVID-19. 

This clinical trial will use Mesenchymal Stromal Cells (MSCs) for the treatment of ARDS, including both COVID-19 positive and COVID-19 negative patients, with the hopes of improving oxygenation.

Design: 

Phase 2B trial 

Goal: 

Test safety and efficacy.